Blueprint Medicines Corporation Stock

Equities

BPMC

US09627Y1091

Biotechnology & Medical Research

Delayed Nasdaq 04:00:00 2024-05-24 pm EDT 5-day change 1st Jan Change
102.8 USD +0.41% Intraday chart for Blueprint Medicines Corporation -2.05% +11.46%
Sales 2024 * 431M Sales 2025 * 653M Capitalization 6.44B
Net income 2024 * -152M Net income 2025 * -104M EV / Sales 2024 * 13.8 x
Net cash position 2024 * 514M Net cash position 2025 * 444M EV / Sales 2025 * 9.18 x
P/E ratio 2024 *
-46.3 x
P/E ratio 2025 *
-63 x
Employees 645
Yield 2024 *
-
Yield 2025 *
0.97%
Free-Float 99.1%
More Fundamentals * Assessed data
Dynamic Chart
Blueprint Medicines Says BLU-222 Combination Well Tolerated for Inhibitor in Type of Breast Cancer MT
Blueprint Medicines Corporation to Present the First Promising and Most Advanced Clinical Data for a CDK2 Inhibitor in Combination with an Approved CDK4/6 Inhibitor in HR+/HER2- Breast Cancer at the 2024 ASCO Annual Meeting CI
Stephens Starts Blueprint Medicines With Overweight Rating, $140 Price Target MT
Blueprint Medicines Insider Sold Shares Worth $1,050,000, According to a Recent SEC Filing MT
Goldman Sachs Adjusts Price Target on Blueprint Medicines to $168 From $121, Maintains Buy Rating MT
Leerink Upgrades Blueprint Medicines to Market Perform, Price Target at $97 MT
Wedbush Raises Blueprint Medicines' Price Target to $120 From $110 After Stronger-Than-Expected Q1 Results, Keeps Outperform Rating MT
Blueprint Medicines Shares Rise After Q1 Swings to Net Income, Revenue Rises MT
Transcript : Blueprint Medicines Corporation, Q1 2024 Earnings Call, May 02, 2024
Earnings Flash (BPMC) BLUEPRINT MEDICINES CORPORATION Posts Q1 Revenue $96.1M, vs. Street Est of $81.4M MT
Blueprint Medicines Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Blueprint Medicines Corporation Revises Revenue Guidance for the Full Year 2024 CI
Transcript : Blueprint Medicines Corporation - Special Call
Blueprint Medicines Insider Sold Shares Worth $2,188,265, According to a Recent SEC Filing MT
Blueprint Medicines Insider Sold Shares Worth $500,000, According to a Recent SEC Filing MT
More news

Latest transcript on Blueprint Medicines Corporation

1 day+0.41%
1 week-2.05%
Current month+12.56%
1 month+10.55%
3 months+8.16%
6 months+50.20%
Current year+11.46%
More quotes
1 week
101.21
Extreme 101.2125
106.02
1 month
90.75
Extreme 90.745
111.02
Current year
72.24
Extreme 72.24
111.02
1 year
43.89
Extreme 43.89
111.02
3 years
37.82
Extreme 37.82
117.86
5 years
37.82
Extreme 37.82
125.61
10 years
13.04
Extreme 13.04
125.61
More quotes
Managers TitleAgeSince
Chief Executive Officer 48 16-01-04
Founder 52 08-09-30
Director of Finance/CFO 52 14-08-31
Members of the board TitleAgeSince
Director/Board Member 65 16-04-13
Founder 52 08-09-30
Director/Board Member 58 16-02-03
More insiders
Date Price Change Volume
24-05-24 102.8 +0.41% 401,436
24-05-23 102.4 -0.31% 551,246
24-05-22 102.7 -0.89% 385,996
24-05-21 103.6 -0.60% 423,398
24-05-20 104.3 -0.67% 468,869

Delayed Quote Nasdaq, May 24, 2024 at 04:00 pm EDT

More quotes
Blueprint Medicines Corporation is a global precision therapy company that is inventing life-changing medicines in two areas of allergy/inflammation and oncology/hematology. The Company delivers its approved medicines, including AYVAKIT/AYVAKYT (avapritinib) and GAVRETO (pralsetinib), to patients in the United States and Europe, and it is globally advancing multiple programs for systemic mastocytosis (SM), lung cancer, breast cancer and other genomically defined cancers, and cancer immunotherapy. Its pipelines also include Elenestinib (BLU-263) (KIT), AYVAKIT (avapritinib) (KIT), Wild-type KIT research program, GAVRETO (pralsetinib) (RET), BLU-945 (EGFR), BLU-525 (EGFR), BLU-451 (EGFR exon 20 insertions), BLU-222 (CDK2), AYVAKIT (PDGFRA), GAVRETO (RET), BLU-222 (CDK2) and BLU-852 (MAP4K1). It is developing elenestinib (BLU-263), an investigational, orally available, potent and highly selective KIT inhibitor, for the treatment of indolent SM and other mast cell disorders.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
102.8 USD
Average target price
119.4 USD
Spread / Average Target
+16.15%
Consensus